跳至主要内容
临床试验/NL-OMON50577
NL-OMON50577已完成不适用

actoferrin in the treatment of Long COVID - LARGO-study

ongziekten0 个研究点目标入组 72 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Subjects aged 18-70 years with proven COVID-19 (positive COVID-19
  • RT-PCR- or antibody test)
  • - Persistent or newly developed long COVID symptoms at least 12 weeks
  • post-primary SARS-CoV-2 infection
  • - Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9

排除标准

  • - Patients admitted to the ICU (COVID-19-related)
  • - COVID-19-related cardiac or pulmonary tissue damage
  • - Acute infection or current systemic immunological disorders
  • - Oral and/or inhaled use of corticosteroids or use of other immune-modulatory
  • - Current psychiatric disorders
  • - Communication difficulties
  • - Pregnant or lactating women
  • - Age >70 years
  • - Patients with milk allergy or a known or suspected allergy or any
  • contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can
  • be used by individuals with lactose intolerance)

研究者

发起方
ongziekten

相似试验